Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Oragenics, Inc. (OGEN : AMEX)
 
 • Company Description   
Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.53 Daily Weekly Monthly
20 Day Moving Average: 1,077,198 shares
Shares Outstanding: 0.82 (millions)
Market Capitalization: $1.26 (millions)
Beta: 0.95
52 Week High: $75.60
52 Week Low: $1.35
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -56.66% -59.00%
12 Week -71.21% -75.85%
Year To Date -86.20% -87.08%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1990 MAIN STREET SUITE 750
-
SARASOTA,FL 34236
USA
ph: 813-286-7900
fax: 813-286-7904
None http://www.oragenics.com
 
 • General Corporate Information   
Officers
Kimberly M. Murphy - Chief Executive Officer; Chief Financial Officer;
Charles L. Pope - Executive Chairman and Director
Joseph Michael Redmond - Interim Principal Executive Officer; President
Robert C. Koski - Director
Frederick W. Telling - Director

Peer Information
Oragenics, Inc. (CORR.)
Oragenics, Inc. (RSPI)
Oragenics, Inc. (CGXP)
Oragenics, Inc. (BGEN)
Oragenics, Inc. (GTBP)
Oragenics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 684023609
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/08/25
Share - Related Items
Shares Outstanding: 0.82
Most Recent Split Date: 6.00 (0.03:1)
Beta: 0.95
Market Capitalization: $1.26 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.95
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 82.86%
vs. Previous Quarter: -9.09%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -3,614.27
12/31/24 - -2,074.19
ROA
06/30/25 - -
03/31/25 - -311.83
12/31/24 - -327.16
Current Ratio
06/30/25 - -
03/31/25 - 1.04
12/31/24 - 0.87
Quick Ratio
06/30/25 - -
03/31/25 - 1.04
12/31/24 - 0.87
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.19
12/31/24 - -0.51
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - -
 

Powered by Zacks Investment Research ©